JP2024537772A5 - - Google Patents
Info
- Publication number
- JP2024537772A5 JP2024537772A5 JP2024519268A JP2024519268A JP2024537772A5 JP 2024537772 A5 JP2024537772 A5 JP 2024537772A5 JP 2024519268 A JP2024519268 A JP 2024519268A JP 2024519268 A JP2024519268 A JP 2024519268A JP 2024537772 A5 JP2024537772 A5 JP 2024537772A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antigen
- binding site
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163250092P | 2021-09-29 | 2021-09-29 | |
| US63/250,092 | 2021-09-29 | ||
| PCT/US2022/077068 WO2023056243A1 (en) | 2021-09-29 | 2022-09-27 | Antibodies targeting baff-r and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024537772A JP2024537772A (ja) | 2024-10-16 |
| JP2024537772A5 true JP2024537772A5 (enExample) | 2025-10-07 |
Family
ID=85780903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024519268A Pending JP2024537772A (ja) | 2021-09-29 | 2022-09-27 | Ｂａｆｆ－ｒを標的化する抗体及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240228645A1 (enExample) |
| EP (1) | EP4408891A4 (enExample) |
| JP (1) | JP2024537772A (enExample) |
| KR (1) | KR20240069787A (enExample) |
| CN (1) | CN118317975A (enExample) |
| AR (1) | AR127163A1 (enExample) |
| AU (1) | AU2022354054A1 (enExample) |
| CA (1) | CA3233246A1 (enExample) |
| IL (1) | IL311600A (enExample) |
| MX (1) | MX2024003913A (enExample) |
| TW (1) | TW202330604A (enExample) |
| WO (1) | WO2023056243A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020015994A2 (pt) | 2018-02-08 | 2020-12-15 | Dragonfly Therapeutics, Inc. | Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer |
| CA3237846A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| KR102835308B1 (ko) | 2018-08-08 | 2025-07-21 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| EP3833392A4 (en) | 2018-08-08 | 2022-05-18 | Dragonfly Therapeutics, Inc. | MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| WO2025067496A1 (zh) * | 2023-09-28 | 2025-04-03 | 南京驯鹿生物技术股份有限公司 | 靶向baff-r的全人源抗体、car-t细胞及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101120021A (zh) * | 2004-12-31 | 2008-02-06 | 基因技术公司 | 结合br3的多肽及其用途 |
| EP2604279A1 (en) * | 2008-03-27 | 2013-06-19 | ZymoGenetics, Inc. | Compositions and methods for inhibiting PDGFRBETA and VEGF-A |
| SI2315780T1 (sl) * | 2008-07-17 | 2015-11-30 | Novartis Ag | Sestavki in postopki uporabe za terapevtska protitelesa |
| CA2748161A1 (en) * | 2008-12-23 | 2010-07-01 | Astrazeneca Ab | Targeted binding agents directed to .alpha.5.beta.1 and uses thereof |
| US9216219B2 (en) * | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| EP4628094A3 (en) * | 2016-06-06 | 2025-12-31 | City of Hope | BAFF-R ANTIBODIES AND THEIR USES |
| WO2021163989A1 (en) * | 2020-02-21 | 2021-08-26 | Yinnuolai Biotech Ltd. | Anti-baff receptor antibodies and uses thereof |
-
2022
- 2022-09-27 AR ARP220102598A patent/AR127163A1/es unknown
- 2022-09-27 JP JP2024519268A patent/JP2024537772A/ja active Pending
- 2022-09-27 EP EP22877491.5A patent/EP4408891A4/en active Pending
- 2022-09-27 MX MX2024003913A patent/MX2024003913A/es unknown
- 2022-09-27 IL IL311600A patent/IL311600A/en unknown
- 2022-09-27 TW TW111136545A patent/TW202330604A/zh unknown
- 2022-09-27 CA CA3233246A patent/CA3233246A1/en active Pending
- 2022-09-27 CN CN202280064772.4A patent/CN118317975A/zh active Pending
- 2022-09-27 AU AU2022354054A patent/AU2022354054A1/en active Pending
- 2022-09-27 WO PCT/US2022/077068 patent/WO2023056243A1/en not_active Ceased
- 2022-09-27 KR KR1020247013643A patent/KR20240069787A/ko active Pending
-
2024
- 2024-03-28 US US18/620,375 patent/US20240228645A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024537772A5 (enExample) | ||
| US11919958B2 (en) | Anti-CD28 compositions | |
| JP2022551757A5 (enExample) | ||
| IL311600A (en) | Antibodies targeting BAFF-R and their use | |
| IL317912A (en) | A combined chimeric antigen receptor targeting CD19 and CD20 and its applications | |
| JP2023524997A5 (enExample) | ||
| JP7854121B2 (ja) | 微小ガイダンス及びナビゲーションコントロール（ｍｉｎｉＧＮＣ）抗体様タンパク質、その製造方法及び使用方法 | |
| JP2021526844A5 (enExample) | ||
| CA3091764A1 (en) | Antibody variable domains targeting cd33, and use thereof | |
| CA3020864A1 (en) | Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof | |
| WO2019101695A1 (en) | Multispecific antigen binding proteins | |
| US20230383012A1 (en) | Antibodies that bind pd-l1, pd-l2, and/or cd28 | |
| JP2024537779A5 (enExample) | ||
| JP2023546766A5 (enExample) | ||
| JP2023525778A5 (enExample) | ||
| JP2024534847A5 (enExample) | ||
| TW202221015A (zh) | 單一及雙靶定配體誘導之t細胞銜接體組合物 | |
| US20250043001A1 (en) | Anti-cd28 compositions | |
| JP2021524451A (ja) | 最適化済みｇｐ４１結合分子及びその使用 | |
| JP2024541476A5 (enExample) | ||
| EP4469478A1 (en) | Bispecific molecule with tunable affinity to a targetted antigen | |
| US20250084186A1 (en) | Anti-cd28 x anti-enpp3 antibodies | |
| JP2023517889A5 (enExample) | ||
| HK40073541A (en) | Miniature guidance and navigation control (minignc) antibody-like proteins and methods of making and using thereof | |
| JP2025505933A5 (enExample) |